CHARLES RIVER LABORATORIES (CRL) Stock Price, Quote, News and Overview
NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD
CRL Quote, Performance and Key Statistics
135.6
+0.62 (+0.46%)
The current stock price of CRL is 135.6 USD. In the past month the price increased by 17.14%. In the past year, price decreased by -37.57%.
CRL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 18.29 | 151.18B | ||
| DHR | DANAHER CORP | 25.17 | 134.17B | ||
| A | AGILENT TECHNOLOGIES INC | 20.66 | 31.27B | ||
| IQV | IQVIA HOLDINGS INC | 12.22 | 24.34B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.08 | 23.67B | ||
| WAT | WATERS CORP | 29.26 | 20.73B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.4 | 14.98B | ||
| ILMN | ILLUMINA INC | 24.19 | 12.75B | ||
| RVTY | REVVITY INC | 18.35 | 10.87B | ||
| ICLR | ICON PLC | 9.26 | 10.48B | ||
| TEM | TEMPUS AI INC | N/A | 10.25B | ||
| QGEN | QIAGEN N.V. | 18.4 | 9.15B |
Related stock screener links
About CRL
Company Profile
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Company Info
CHARLES RIVER LABORATORIES
251 Ballardvale St
Wilmington MASSACHUSETTS 01887 US
CEO: James C. Foster
Employees: 19400
Phone: 17812226000
CHARLES RIVER LABORATORIES / CRL FAQ
What is the stock price of CHARLES RIVER LABORATORIES today?
The current stock price of CRL is 135.6 USD. The price increased by 0.46% in the last trading session.
What is the ticker symbol for CHARLES RIVER LABORATORIES stock?
The exchange symbol of CHARLES RIVER LABORATORIES is CRL and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is CRL stock listed?
CRL stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for CHARLES RIVER LABORATORIES stock?
24 analysts have analysed CRL and the average price target is 150.62 USD. This implies a price increase of 11.08% is expected in the next year compared to the current price of 135.6. Check the CHARLES RIVER LABORATORIES stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHARLES RIVER LABORATORIES worth?
CHARLES RIVER LABORATORIES (CRL) has a market capitalization of 6.66B USD. This makes CRL a Mid Cap stock.
How many employees does CHARLES RIVER LABORATORIES have?
CHARLES RIVER LABORATORIES (CRL) currently has 19400 employees.
What are the support and resistance levels for CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a support level at 135.59 and a resistance level at 139.36. Check the full technical report for a detailed analysis of CRL support and resistance levels.
Is CHARLES RIVER LABORATORIES (CRL) expected to grow?
The Revenue of CHARLES RIVER LABORATORIES (CRL) is expected to decline by -3.49% in the next year. Check the estimates tab for more information on the CRL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CHARLES RIVER LABORATORIES (CRL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRL, evaluating the profitability, health, valuation and growth aspects
- CHARLES RIVER LABORATORIES (CRL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHARLES RIVER LABORATORIES (CRL) Sales and EPS estimates to see what analysts future expectations are.
- CHARLES RIVER LABORATORIES (CRL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHARLES RIVER LABORATORIES (CRL) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHARLES RIVER LABORATORIES (CRL) Stock Chart to make your own analysis
- CHARLES RIVER LABORATORIES (CRL) Latest news and press-releases to stay up to date.
Does CHARLES RIVER LABORATORIES (CRL) stock pay dividends?
CRL does not pay a dividend.
When does CHARLES RIVER LABORATORIES (CRL) report earnings?
CHARLES RIVER LABORATORIES (CRL) will report earnings on 2025-08-05, before the market open.
What is the Price/Earnings (PE) ratio of CHARLES RIVER LABORATORIES (CRL)?
The PE ratio for CHARLES RIVER LABORATORIES (CRL) is 13.05. This is based on the reported non-GAAP earnings per share of 10.39 and the current share price of 135.6 USD. Check the full fundamental report for a full analysis of the valuation metrics for CRL.
What is the Short Interest ratio of CHARLES RIVER LABORATORIES (CRL) stock?
The outstanding short interest for CHARLES RIVER LABORATORIES (CRL) is 5.43% of its float. Check the ownership tab for more information on the CRL short interest.
CRL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CRL. When comparing the yearly performance of all stocks, CRL is a bad performer in the overall market: 84.9% of all stocks are doing better.
CRL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRL. Both the profitability and the financial health of CRL get a neutral evaluation. Nothing too spectacular is happening here.
CRL Financial Highlights
Over the last trailing twelve months CRL reported a non-GAAP Earnings per Share(EPS) of 10.39. The EPS increased by 2.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.42% | ||
| ROE | -0.99% | ||
| Debt/Equity | 0.79 |
CRL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 63% to CRL. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of -6.16% and a revenue growth -3.49% for CRL